Oubon Biotech

Hobtest (Jiangsu Hobtest Bio-Medical Co., Ltd.) is a leading Chinese biotechnology company specializing in the development, production, and sale of in vitro diagnostic (IVD) reagents and instruments. The company focuses on three primary therapeutic areas: allergy testing, autoimmune disease diagnosis, and infectious disease screening. Hobtest leverages its proprietary nano-magnetic particle chemiluminescence technology to provide high-throughput, automated diagnostic solutions for clinical laboratories. In late 2024, the company became a strategic subsidiary of Sino Biopharmaceutical (CP Pharmaceutical Group), which acquired a controlling interest to expand its presence in the respiratory and autoimmune diagnostic markets.